Mechanisms of Apoptosis Resistance to NK Cell-Mediated Cytotoxicity in Cancer
Open accessThe DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Abstract
Natural killer (NK) cells are major contributors to immunosurveillance and control of tumor development by inducing apoptosis of malignant cells. Among the main mechanisms involved in NK cell-mediated cytotoxicity, the death receptor pathway and the release of granules containing perforin/granzymes stand out due to their efficacy in eliminating tumor cells. However, accumulated evidence suggest a profound immune suppression in the context of tumor progression affecting effector cells, such as NK cells, leading to decreased cytotoxicity. This diminished capability, together with the development of resistance to apoptosis by cancer cells, favor the loss of immunogenicity and promote immunosuppression, thus partially inducing NK cell-mediated killing resistance. Altered expression patterns of pro- and anti-apoptotic proteins along with genetic background comprise the main mechanisms of resistance to NK cell-related apoptosis. Herein, we summarize the main effector cytotoxic mechanisms against tumor cells, as well as the major resistance strategies acquired by tumor cells that hamper the extrinsic and intrinsic apoptotic pathways related to NK cell-mediated killing.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A framework for advancing our understanding of cancer-associated fibroblasts
Sahai, E., Astsaturov, I., Cukierman, E., DeNardo, D. G., Egeblad, M., Evans, R. M., Fearon, D., Greten, F. R., Hingorani, S. R., Hunter, T., et al. (2020) · Nature Reviews Cancer · doi:10.1038/s41568-019-0238-1 · Cited by 3,863
Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo.
Walczak, H., Miller, R. E., Ariail, K., Gliniak, B., Griffith, T. S., Kubin, M., Chin, W., Jones, J., Woodward, A., Le, T., et al. (1999) · Nature Medicine · doi:10.1038/5517 · Cited by 2,497
Safety and antitumor activity of recombinant soluble Apo2 ligand
Ashkenazi, A., Pai, R. C., Fong, S., Leung, S., Lawrence, D. A., Marsters, S. A., Blackie, C., Chang, L., McMurtrey, A. E., Hebert, A., et al. (1999) · Journal of Clinical Investigation · doi:10.1172/jci6926 · Cited by 2,213
Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and Treg cells
Facciabene, A., Peng, X., Hagemann, I. S., Balint, K., Barchetti, A., Wang, L.-P., Gimotty, P. A., Gilks, C. B., Lal, P., Zhang, L., et al. (2011) · Nature · doi:10.1038/nature10169 · Cited by 1,376
Perforin and granzymes: function, dysfunction and human pathology
Voskoboinik, I., Whisstock, J. C., & Trapani, J. A. (2015) · Nature Reviews Immunology · doi:10.1038/nri3839 · Cited by 1,327
Chang, F., Lee, J. T., Navolanic, P. M., Steelman, L. S., Shelton, J. G., Blalock, W. L., Franklin, R. A., & McCubrey, J. A. (2003) · Leukemia · doi:10.1038/sj.leu.2402824 · Cited by 1,176
Identification and validation of oncogenes in liver cancer using an integrative oncogenomic approach
Zender, L., Spector, M. S., Xue, W., Flemming, P., Cordon-Cardo, C., Silke, J., Fan, S.-T., Luk, J. M., Wigler, M., Hannon, G. J., et al. (2006) · Cell · doi:10.1016/j.cell.2006.05.030 · Cited by 1,065 · cited 1×
“c-IAP1 Esophageal, liver, lung and ovarian carcinomas [73,74]”
BackgroundPerforin-mediated target-cell death and immune homeostasis
Voskoboinik, I., Smyth, M. J., & Trapani, J. A. (2006) · Nature reviews. Immunology · doi:10.1038/nri1983 · Cited by 592 · cited 1×
“PRF1 monomers are glycoproteins that, similarly to the complement membrane attack complex, aggregate and form a pore in the membrane of the tumor cell, hence allowing the internalization of GZMs into the cytosol and eliciting osmotic imbalance [50].”
BackgroundExploring the TRAILs less travelled: TRAIL in cancer biology and therapy
von Karstedt, S., Montinaro, A., & Walczak, H. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2017.28 · Cited by 556 · cited 2×
“TRAIL expression may be detected on immune cells from myeloid and lymphoid origin, but, interestingly, peripheral blood NK cells do not express membrane TRAIL and yet, it is constitutively expressed on liver NK cells in humans [20,21].”
BackgroundMembrane-bound Fas ligand only is essential for Fas-induced apoptosis
O’ Reilly, L. A., Tai, L., Lee, L., Kruse, E. A., Grabow, S., Fairlie, W. D., Haynes, N. M., Tarlinton, D. M., Zhang, J.-G., Belz, G. T., et al. (2009) · Nature · doi:10.1038/nature08402 · Cited by 400
Erler, J. T., Cawthorne, C. J., Williams, K. J., Koritzinsky, M., Wouters, B. G., Wilson, C., Miller, C., Demonacos, C., Stratford, I. J., & Dive, C. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.7.2875-2889.2004 · Cited by 400
Rudnick, S. I., Lou, J., Shaller, C. C., Tang, Y., Klein-Szanto, A. J. P., Weiner, L. M., Marks, J. D., & Adams, G. P. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-2277 · Cited by 365
Baginska, J., Viry, E., Berchem, G., Poli, A., Noman, M. Z., van Moer, K., Medves, S., Zimmer, J., Oudin, A., Niclou, S. P., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1304790110 · Cited by 344
Zhang, R., Qi, F., Zhao, F., Li, G., Shao, S., Zhang, X., Yuan, L., & Feng, Y. (2019) · Cell Death & Disease · doi:10.1038/s41419-019-1435-2 · Cited by 343
Chiu, D. K., Xu, I. M., Lai, R. K., Tse, A. P., Wei, L. L., Koh, H., Li, L. L., Lee, D., Lo, R. C., Wong, C., et al. (2016) · Hepatology · doi:10.1002/hep.28655 · Cited by 241
Rubio-Moscardo, F. (2005) · Blood · doi:10.1182/blood-2005-05-2013 · Cited by 157 · cited 4×
“TRAIL-R2 Allelic deletion B-NHL [92] Breast cancer [93]”
BackgroundInfluentialImpairment of NKG2D-Mediated Tumor Immunity by TGF-β
Lazarova, M., & Steinle, A. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02689 · Cited by 149
Tittarelli, A., Janji, B., Van Moer, K., Noman, M. Z., & Chouaib, S. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.651547 · Cited by 105
Inoue, K., Kohno, T., Takakura, S., Hayashi, Y., Mizoguchi, H., & Yokota, J. (2000) · Leukemia Research · doi:10.1016/s0145-2126(99)00182-4 · Cited by 45 · cited 3×
“T-ALL [79] CLL [80] Burkitt’s lymphoma [81]”
Background
Cited by
A framework for advancing our understanding of cancer-associated fibroblasts
Sahai, E., Astsaturov, I., Cukierman, E., DeNardo, D. G., Egeblad, M., Evans, R. M., Fearon, D., Greten, F. R., Hingorani, S. R., Hunter, T., et al. (2020) · Nature Reviews Cancer · doi:10.1038/s41568-019-0238-1 · Cited by 3,863
Hsu, S.-K., Li, C.-Y., Lin, I.-L., Syue, W.-J., Chen, Y.-F., Cheng, K.-C., Teng, Y.-N., Lin, Y.-H., Yen, C.-H., & Chiu, C.-C. (2021) · Theranostics · doi:10.7150/thno.62521 · Cited by 484
Peña-Romero, A. C., & Orenes-Piñero, E. (2022) · Cancers · doi:10.3390/cancers14071681 · Cited by 257
Hu, B., Xin, Y., Hu, G., Li, K., & Tan, Y. (2023) · APL Bioengineering · doi:10.1063/5.0156628 · Cited by 36
Lu, Z., Chen, C., Zhang, H., Li, B., Liu, Y., Guo, J., Xu, R., Shi, K., Ma, Q., Zhang, M., et al. (2025) · Nature Cancer · doi:10.1038/s43018-025-01031-z · Cited by 4
“The sequences of oligonucleotides are provided in Supplementary Table 39.”
Metadata
- Authors
- Sordo-Bahamonde, C., Lorenzo-Herrero, S., Payer, Á. R., Gonzalez, S., & López-Soto, A.
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2020-05-25
- Volume
- 21
- Issue
- 10
- Pages
- 3726
- ISSN
- 1422-0067 (ISSN-L)
- OpenAlex
- W3028560143
- Cited by
- 123
- References
- 19
- FWCI
- 4.84
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.